Shopping Cart

Your shopping cart is currently empty

CFI-402257

Name: CFI-402257
Brand: TargetMol
SKU: T22289
Price: 65 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Synonyms:

Catalog No. T22289 Copy Product Info

Purity: 99.51%

😃Good

CFI-402257 (Luvixasertib) is a highly selective oral TTK (Mps1, Monopolar Spindle 1) kinase inhibitor that potently inhibits TTK kinase activity (Mps1 Ki = 0.09 nM；EC50 = 6.5 nM). It is intended for use in research on hepatocellular carcinoma and breast cancer.

Cas No. 1610759-22-2

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$65	In Stock	In Stock
5 mg	$155	In Stock	In Stock
10 mg	$221	In Stock	In Stock
25 mg	$403	In Stock	In Stock
50 mg	$603	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.51%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR HPLC

Product Introduction

Bioactivity

Description	CFI-402257 (Luvixasertib) is a highly selective oral TTK (Mps1, Monopolar Spindle 1) kinase inhibitor that potently inhibits TTK kinase activity (Mps1 Ki = 0.09 nM；EC50 = 6.5 nM). It is intended for use in research on hepatocellular carcinoma and breast cancer.
Targets & IC50	TTK:1.7 nM, TTK:0.1 nM (Ki), Mps1:0.09 nM (Ki), Mps1:6.5 nM (EC50)
In vitro	Methods: MHCC97L cells were treated with 100 nM CFI-402257 for 72 hours, followed by flow cytometric analysis of DNA content. Results: CFI-402257 induced a significant increase in the proportion of aneuploid cells. [1]
In vivo	Methods: MHCC97L-luc cells were implanted in BALB/cAnN-nu mice. Treatment commenced 2 weeks post-implantation when tumor formation initiated. CFI-402257 was administered orally via gavage at 30 mg/kg once daily for 4 consecutive weeks. Results: Tumor volume significantly decreased, and the number of pulmonary metastatic nodules markedly reduced. [1] Methods: A carotid artery wire injury model was established in C57BL/6 mice via carotid artery wire injury. Treatment commenced postoperatively with oral gavage of CFI-402257 at 30 mg/kg once daily for 28 consecutive days. Results: The area of newly formed endothelium and the intima-media ratio were significantly reduced, while re-endothelialization remained unaffected (confirmed by CD31 staining), demonstrating superiority over conventional drug-eluting stents. [2]

Chemical Properties

Molecular Weight	498.58
Formula	C₂₈H₃₀N₆O₃
Cas No.	1610759-22-2
Smiles	N(C[C@H]1C[C@@](C)(O)C1)C=2N3C(=C(C=N3)C4=CC(C)=C(C(NC5CC5)=O)C=C4)N=C(OC=6C=CC=NC6)C2
Relative Density.	1.42 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 37.7 mg/mL (75.61 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.0057 mL	10.0285 mL	20.0570 mL	100.2848 mL
5 mM	0.4011 mL	2.0057 mL	4.0114 mL	20.0570 mL
10 mM	0.2006 mL	1.0028 mL	2.0057 mL	10.0285 mL
20 mM	0.1003 mL	0.5014 mL	1.0028 mL	5.0142 mL
50 mM	0.0401 mL	0.2006 mL	0.4011 mL	2.0057 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.